Item 7.01 Regulation FD Disclosure.
On August 1, 2022, Acumen Pharmaceuticals, Inc. (the “Company”) issued a press
release announcing it will be presenting a poster with an accompanying
presentation regarding the preparation and qualification of soluble AßOs for use
in bioanalytical assays supporting Alzheimer’s disease therapeutics during the
2022 Alzheimer’s Association International Conference taking place from July 31
through August 4, 2022 in San Diego, California (the “AAIC 22”). The poster will
be presented at the conference on August 3, 2022. A copy of the press release
and of the poster being presented are attached as Exhibits 99.1 and 99.2,
respectively, to this Current Report on Form 8-K (this “Report”).
The information in this Report, including Exhibit 99.1 and Exhibit 99.2 hereto,
is furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), or otherwise subject to the liabilities of that Section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended, or the Exchange Act, except as expressly set forth by specific
reference in such filing. The Company’s submission of this Report shall not be
deemed an admission as to the materiality of any information required to be
disclosed solely to satisfy the requirements of Regulation FD.
This Report and Exhibit 99.1 and Exhibit 99.2 hereto contain forward-looking
statements within the meaning of the federal securities laws. These
forward-looking statements are based on current expectations and are not
guarantees of future performance. Further, the forward-looking statements are
subject to limitations listed in Exhibit 99.1 and in the other reports of the
Company filed with the Securities and Exchange Commission, including that actual
events or results may differ materially from those in the forward-looking
statements.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Press Release, dated August 1, 2022
99.2 AAIC 22 Poster: Preparation and qualification of soluble AßOs for
use in bioanalytical assays supporting AD therapeutics
104 Cover Page Interactive Data File (the cover page XBRL tags are
embedded within the inline XBRL document)
——————————————————————————–
© Edgar Online, source Glimpses
postbrexitcompliance.com 